Navigation Links
Cell Therapeutics to Resume Trading on MTA and NASDAQ
Date:2/17/2009

SEATTLE, Feb. 17 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that, following the issuance of a press release in Italy in response to information requested by the Italian securities regulatory authority, CONSOB, regarding CTI's business operations and financial condition, which was also furnished on a Form 8-K in the U.S. on February 17, 2009, the Borsa Italiana has confirmed that it will re-initiate trading in CTI's shares effective with the open of trading in Italy on February 18, 2009. Based on the foregoing and CTI's communications with NASDAQ, CTI also anticipates that NASDAQ will re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ on February 18, 2009.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that that NASDAQ may not re-initiate trading in the Company's shares prior to the open of the regular trading session on NASDAQ within the anticipated time frame, the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... ... will bring together more than 200 of the country’s top healthcare executives to ... , “The true benefit of the Forum is the provider-centric perspective, experience, expertise ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a ... for the fourth quarter and full year ended December 31, 2015 on Monday, February ... and webcast for the investment community following the release at 4:30 PM ET. Investors ...
(Date:2/10/2016)... ... 2016 , ... Pediatric therapists are challenged to use evidence ... the Goal Attainment Scale (GAS) captures 20% more change in outcomes than other ... the Goal Attainment Scale, Education Resources Inc. is offering a course focused on ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club at Ibis ... prestigious Distinguished Emerald Club of the World award, as determined by the annual ... the most respected trade publications serving private clubs. , “We’d like to congratulate ...
(Date:2/10/2016)... , ... February 10, 2016 ... ... – 1 UNF Drive, Jacksonville, FL 32224, February 26th: Amateur & Professional ... Elite Division - Time: 7:00pm – 10:00pm | Ticket Prices $30, Social ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Corporation ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS), ... its financial results for the second quarter of fiscal 2016 (three ... Financial Results for the Second Quarter of ... Revenue for the second quarter of fiscal 2016 was $4.5 ... Cash receipts from customers for the second quarter of fiscal 2016 ...
(Date:2/9/2016)... February 9, 2016 ... heute den Abschluss eines Kooperationsvertrags mit 10x ... Lösungen in den Bereichen Next-Generation-Sequencing (NGS), Single-Cell-Biology ... ; Frankfurt Prime Standard: QIA) gab heute ... für die Entwicklung und Förderung umfassender Lösungen ...
(Date:2/9/2016)... February 9, 2016 QGEN ... collaboration with 10x Genomics to develop and promote ... and bioinformatics. --> QGEN ; Frankfurt ... 10x Genomics to develop and promote comprehensive solutions ... --> QIAGEN N.V. (NASDAQ: QGEN ...
Breaking Medicine Technology: